Jeffrey Fineman, MD

Pediatric critical care specialist

Dr. Jeffrey Fineman is a pediatric critical care specialist, or intensivist, and the division chief of Critical Care. He also is an associate investigator of the Cardiovascular Research Institute. His research has led to new therapies for pulmonary hypertension, including a drug called inhaled nitric oxide, which was approved by the U.S. Food and Drug Administration. Fineman's research has focused on diseases related to pulmonary circulation. In particular, he has been interested in the pathophysiology of pulmonary hypertension and heads a laboratory, funded by the National Institutes of Health, for these investigations.

Fineman completed undergraduate training at the State University of New York, Binghamton, medical training at New York University and pediatric training at New York University's Bellevue Medical Center, where he served as pediatric chief resident. He completed a pediatric critical care fellowship at UCSF in 1988 and joined the staff of UCSF Benioff Children's Hospital in 1990.


Pediatric Cardiac Intensive Care Unit
1975 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-1955
Fax: (415) 353-9144

Pediatric Intensive Care Unit
1975 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-1352

Pulmonary Hypertension Program
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 476-3679
Fax: (415) 476-5363

More about Jeffrey Fineman


New York University 1984


New York University, Pediatrics 1987


UCSF Medical Center, Critical Care Medicine 1990

Selected Research and Publications

  1. Zinter MS, Melton A, Sabnis AJ, Dvorak CC, Elicker BM, Nawaytou HM, Kameny RJ, Fineman JR. Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale. Leuk Lymphoma. 2017 Sep 28; 1-4.
  2. Kameny RJ, Colglazier E, Nawaytou H, Moore P, Reddy VM, Teitel D, Fineman JR. Pushing the envelope: a treat and repair strategy for patients with advanced pulmonary hypertension associated with congenital heart disease. Pulm Circ. 2017 Jul-Sep; 7(3):747-751.
  3. Black SM, Field-Ridley A, Sharma S, Kumar S, Keller RL, Kameny R, Maltepe E, Datar SA, Fineman JR. Altered Carnitine Homeostasis in Children With Increased Pulmonary Blood Flow Due to Ventricular Septal Defects. Pediatr Crit Care Med. 2017 Jul 18.
  4. Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, Hanna B, Romer L, Keller RL, Fineman J, Steinhorn R, Kinsella JP, Ivy DD, Rosenzweig EB, Raj U, Humpl T, Abman SH. Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia. J Pediatr. 2017 Sep; 188:24-34.e1.
  5. Mahgoub L, Kaddoura T, Kameny AR, Lopez Ortego P, Vanderlaan RD, Kakadekar A, Dicke F, Rebeyka I, Calderone CA, Redington A, Del Cerro MJ, Fineman J, Adatia I. Pulmonary vein stenosis of ex-premature infants with pulmonary hypertension and bronchopulmonary dysplasia, epidemiology, and survival from a multicenter cohort. Pediatr Pulmonol. 2017 Aug; 52(8):1063-1070.
  6. Kameny RJ, Fineman JR. The Prescient Prognosticator? Hepatoma-derived Growth Factor in Pulmonary Hypertension. Am J Respir Crit Care Med. 2016 Nov 15; 194(10):1186-1187.
  7. Boehme J, Sun X, Tormos KV, Gong W, Kellner M, Datar SA, Kameny RJ, Yuan JX, Raff GW, Fineman JR, Black SM, Maltepe E. Pulmonary artery smooth muscle cell hyperproliferation and metabolic shift triggered by pulmonary overcirculation. Am J Physiol Heart Circ Physiol. 2016 Oct 01; 311(4):H944-H957.
  8. Steinhorn RH, Fineman J, Kusic-Pajic A, Cornelisse P, Gehin M, Nowbakht P, Pierce CM, Beghetti M. Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial. J Pediatr. 2016 Oct; 177:90-96.e3.
  9. Sun X, Kellner M, Desai AA, Wang T, Lu Q, Kangath A, Qu N, Klinger C, Fratz S, Yuan JX, Jacobson JR, Garcia JG, Rafikov R, Fineman JR, Black SM. Asymmetric Dimethylarginine Stimulates Akt1 Phosphorylation via Heat Shock Protein 70-Facilitated Carboxyl-Terminal Modulator Protein Degradation in Pulmonary Arterial Endothelial Cells. Am J Respir Cell Mol Biol. 2016 Aug; 55(2):275-87.
  10. Oishi P, Fineman JR. Pulmonary Hypertension. Pediatr Crit Care Med. 2016 Aug; 17(8 Suppl 1):S140-5.
  11. Datar SA, Gong W, He Y, Johengen M, Kameny RJ, Raff GW, Maltepe E, Oishi PE, Fineman JR. Disrupted NOS signaling in lymphatic endothelial cells exposed to chronically increased pulmonary lymph flow. Am J Physiol Heart Circ Physiol. 2016 Jul 01; 311(1):H137-45.
  12. Rafikova O, Meadows ML, Kinchen JM, Mohney RP, Maltepe E, Desai AA, Yuan JX, Garcia JG, Fineman JR, Rafikov R, Black SM. Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed Rat Lung. PLoS One. 2016; 11(3):e0150480.
  13. Balkin EM, Olson ED, Robertson L, Adatia I, Fineman JR, Keller RL. Change in Pediatric Functional Classification During Treatment and Morbidity and Mortality in Children with Pulmonary Hypertension. Pediatr Cardiol. 2016 Apr; 37(4):756-64.
  14. Chen Q, Varga M, Wang X, Haddad DJ, An S, Medzikovic L, Derakhshandeh R, Kostyushev DS, Zhang Y, Clifford BT, Luu E, Danforth OM, Rafikov R, Gong W, Black SM, Suchkov SV, Fineman JR, Heiss C, Aschbacher K, Yeghiazarians Y, Springer ML. Overexpression of Nitric Oxide Synthase Restores Circulating Angiogenic Cell Function in Patients With Coronary Artery Disease: Implications for Autologous Cell Therapy for Myocardial Infarction. J Am Heart Assoc. 2016 Jan 06; 5(1).
  15. Kinsella JP, Steinhorn RH, Krishnan US, Feinstein JA, Adatia I, Austin ED, Rosenzweig EB, Everett AD, Fineman JR, Hanna BD, Hopper RK, Humpl T, Ivy DD, Keller RL, Mullen MP, Raj JU, Wessel DL, Abman SH. Recommendations for the Use of Inhaled Nitric Oxide Therapy in Premature Newborns with Severe Pulmonary Hypertension. J Pediatr. 2016 Mar; 170:312-4.
  16. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Th├ębaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015 Nov 24; 132(21):2037-99.
  17. Rafikov R, Sun X, Rafikova O, Meadows ML, Desai AA, Khalpey Z, Yuan JX, Fineman JR, Black SM. Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells. Redox Biol. 2015 Dec; 6:278-86.
  18. Olson E, Lusk LA, Fineman JR, Robertson L, Keller RL. Short-Term Treprostinil Use in Infants with Congenital Diaphragmatic Hernia following Repair. J Pediatr. 2015 Sep; 167(3):762-4.
  19. Kameny RJ, He Y, Morris C, Sun C, Johengen M, Gong W, Raff GW, Datar SA, Oishi PE, Fineman JR. Right ventricular nitric oxide signaling in an ovine model of congenital heart disease: a preserved fetal phenotype. Am J Physiol Heart Circ Physiol. 2015 Jul 01; 309(1):H157-65.
  20. Wellnitz K, Harris IS, Sapru A, Fineman JR, Radman M. Longitudinal development of obesity in the post-Fontan population. Eur J Clin Nutr. 2015 Oct; 69(10):1105-8.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.